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Abstract
Background: Allergic rhinitis is regarded as an imbalanced Th1/Th2 cell-mediated response. The present study
used microarray analysis to compare gene expression levels between allergic rhinitis patients before and after a
series of acupoint herbal plaster applications.
Methods: In this experimental pilot study, volunteers experiencing sneezing, runny nose, and congestion for more
than 9 months in the year following initial diagnoses were included after diagnostic confirmation by
otolaryngologists to exclude patients with sinusitis and nasal polyps. Patients with persistent allergic rhinitis each
received four acupoint herbal plaster treatments applied using the moxibustion technique. Clinical outcomes were
evaluated using the Rhinitis Quality of Life Questionnaire (RQLQ). Peripheral blood samples were analyzed using an
ImmunoCAP Phadiatop test, and patients were classified as phadiatop (Ph)-positive or -negative. Microarray results
were analyzed for genes that were differentially expressed between (1) Ph-positive and -negative patients treated
with herbal plaster; and (2) before and after herbal plaster treatment in the Ph-positive patient group. Unsupervised
and supervised methods were used for gene-expression data analysis.
Results: Nineteen Ph-positive and four Ph-negative participants with persistent allergic rhinitis were included in the
study. RQLQ results indicated that the 19 Ph-positive volunteers experienced improvement in six of seven
categories following acupoint herbal plaster treatments, whereas the four Ph-negative participants reported
improvement in only two categories. Hierarchical clustering and principle component analysis of the gene
expression profiles of Ph-positive and –negative participants indicated the groups exhibited distinct physiological
responses to acupoint herbal treatment. Evaluation of gene networks using MetaCore identified that the “Immune
response_IL-13 signaling via JAK-STAT” and the “Inflammation_Interferon signaling” were down- and up-regulated,
respectively, among Ph-positive subjects.
Conclusions: In this preliminary study, we find that the IL-13 immune response via JAK-STAT signaling and
interferon inflammation signaling were down- and upregulated, respectively, in the Ph-positive group. Further
studies are required to verify these pathways in Ph-positive patients, and to determine the mechanism of such
pathway dysregulation.
Trial registration: ClinicalTrials.gov: NCT02486159. Registered 30 Jun 2015.
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Background
Many patients with allergic rhinitis have chosen comple-
mentary and alternative medicine (CAM), including
traditional Chinese medicine (TCM) or acupuncture [1, 2],
as they have found CAM to be more attractive and less
invasive [1]. The World Health Organization (WHO)
published an article examining CAM therapies for allergic
rhinitis and asthma [2], which include major contributions
from TCM and deserve our continued study to assess
therapeutic efficacies and mechanisms. In addition to
acupuncture and TCM to treat allergic rhinitis, acupoint
herbal plaster applications have recently been used widely
in Taiwan [3–5] and mainland China [6, 7] due to the non-
invasive and easy to manipulate nature of these treatments.
An herbal plaster is applied with a drug applicator using a
technique akin to moxibustion, stimulating the skin at
specific acupuncture points [3, 4]. Acupoint herbal plaster
methods have been recommend for allergic rhinitis begin-
ning in 2009 [8], and practitioners throughout Taiwan and
China use similar approaches in the composition of herbal
medicine, the herbal medicine application operating
process [9] and what acupoints are used [10]. Clinical
research regarding the application of acupoint therapy for
allergic rhinitis has increased, and evidence-based methods
have validated its efficacy and safety [7, 9–11]. However,
the majority of these studies are clinical trials; therefore, the
efficacy and mechanisms of acupoint herbal plaster
treatment need to be validated via mechanistic, molecular
methods [2, 9, 12].
We previously studied the effect of herbal plaster
treatment for allergic rhinitis [13]. Ours was the first com-
prehensive clinical outcome assessment of acupoint herbal
plaster therapy for allergic rhinitis using the Rhinoconjunc-
tivitis and Rhinitis Quality of Life Questionnaire (RQLQ)
[14]. We showed that acupoint herbal plaster for the treat-
ment of allergic rhinitis is safe, effective, and associated with
high compliance rates. Here, we aimed to perform a pilot
study for acupoint herbal plaster treatment based on our
previous microarray experience. Our laboratory has rich
microarray experience that combines the Genomic
Medicine Research Core Laboratory (GMRCL) [15],
clinicians in the Department of Chinese Medicine at Chang
Gung Memorial Hospital, and bioinformatics specialists.
We performed chip analysis before and after acupuncture
treatment in allergic rhinitis patients [16, 17]. We used
cDNA microarray and oligonucleotide microarray analyses
to investigate the influence of acupuncture on RNA expres-
sion profiles using blood samples from patients with allergic
rhinitis. We used the RQLQ and statistical analysis to assess
clinical outcomes [14]. The results of our microarray
analysis were associated with the RQLQ to obtain our final
conclusions.
Following exposure to allergens, allergic rhinitis
patients exhibit immunoglobulin E (IgE), mast cell, and
T helper (Th)2 lymphocyte immune responses related to
(1) sensitization and memory, (2) the early phase, and
(3) the late phase [18, 19]. The early phase can induce
sneezing, nasal itching, runny and congested nasal
passages, and other symptoms. The late phase
contributes to patient fatigue, malaise, irritability, and
other symptoms. Allergic rhinitis is regarded as an
imbalanced Th1/Th2 cell-mediated response [20, 21].
Th1 cells primarily secrete IL-2, IFNγ, IL-3, and
GM-CSF; whereas Th2 cells secrete IL-3, IL-4, IL-5,
IL-10, IL-13, and GM-CSF [22]. Dominant Th2
cytokines can enhance allergen-specific IgE, which plays
an important role in allergic inflammation [18, 20].
Studies using DNA microarray have indicated an
imbalance in the T-helper cell-mediated immune system
in patients with allergic rhinitis [23, 24]. Genes encoding
chemokines and their receptors were elevated in this
analysis; these genes play important roles in the Th2
response [24, 25].
According to our previous study, peripheral blood
samples collected from allergic rhinitis patients before
and after acupuncture treatment and analyzed by cDNA
microarray analysis indicated an improvement in the
counterbalance between pro-inflammatory cytokines
derived from Th1 cells and anti-inflammatory cytokines
derived from Th2 cells [16]. Nasal allergic reactions in
patients with allergic rhinitis were inhibited by Th1 cells
and were not promoted by Th2 cells following acupunc-
ture treatment [16]. Although strengthening the Th1
response is regarded as a novel therapeutic target for
allergic rhinitis, it has not yet been applied in clinical
practice [19, 21]. We have published that acupuncture
treatment may be another way to restructure Th1 and
Th2 responses in patients with allergic rhinitis [16].
ImmunoCAP Phadiatop is a blood test widely used by
ENT specialists in Taiwan to detect serum allergen-
specific IgE antibodies [26, 27]. Among normal controls
and atopic patients, the frequency of Ph-positive patients
was 1 of 47 and 49 of 53, respectively [26]. In our
previous study [17], Th1 and Th2 cells were suppressed
after acupuncture treatment with group differences
between Phadiatop (Ph)-positive and Ph-negative pa-
tients regarding gene expression characteristics and
physiological responses. Studies have shown that the
reduction in allergic inflammation and the restored Th1/
Th2 (and Treg/Th2) equilibrium following acupuncture
are sustained [17].
In this pilot study, we examined changes in gene
expression associated with acupoint herbal plaster for
allergic rhinitis. Using microarray, we compared gene
expression levels in allergic rhinitis patients before and
after a series of acupoint herbal plaster applications. This
study applies EBM and supports the use of acupoint
herbal therapy to treat allergic rhinitis.
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Methods
Acupoint herbal plaster treatment
This pilot study was designed using an intervention model
with single group assignment. Allergic rhinitis patients were
included after their diagnoses were confirmed, and were
treated with four applications of herbal plaster. The clinical
portion of this study was conducted at the Department of
Acupuncture and Moxibustion, Center for Traditional
Chinese Medicine, Chang Gung Memorial Hospital from
October 2009 to March 2010. Patients (age, 18–45 y) were
eligible who met the following criteria: (1) exhibited sneez-
ing, runny nose, and congestion for more than 9 months of
the year [18]; (2) did not take medication in the previous
month; and (3) provided written consent to enter a Chang
Gung Memorial Hospital Institutional Review Board (IRB)-
approved human trial. Patient diagnoses were confirmed by
the following clinical and biochemical tests, which were
performed by otolaryngologists: (1) physical examination;
(2) anterior rhinoscopy; (3) ImmunoCAP Phadiatop
(InVitroSight, Phadia AB, Uppsala, Sweden), determination
of specified serum IgE antibodies to detect inhalant allergens
[26, 27]. Patients were included in the trial after their initial
diagnoses were confirmed [18, 28]. Patients with sinusitis or
nasal polyps, or those who were unwilling or unable to
complete the full course of treatment were excluded from
the trial. All included patients were diagnosed with allergic
rhinitis that was consistent with persistent allergic rhinitis
according to ARIA’s new classification system. The ARIA
system includes the following rhinitis symptoms and quality
of life variables: duration, which includes intermittent or
persistent allergic rhinitis; and nasal allergy symptoms,
which must occur more than 4 days per week for 4 months
per year to qualify as persistent allergic rhinitis [29, 30].
In total, 23 study patients received acupoint herbal plaster
applications every 7–10 days over a 4-week period for a
total of 4 applications. The herbal plaster consisted of mus-
tard seed, fumarate, asarum, angelica, cinnamon, and ginger
at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was
prepared by dissolving the ginger in water and adding the
powder to form a plaster. Mixtures were formed into cakes
of approximately 1.5 × 1.5 × 0.5 cm3 [13] and were held in
position using plastic sheets. The following nine acupoints
were selected: Dazhui (GV14), Feishu (BL13, both sides),
Gaohuang (BL43, both sides), Shenshu (BL23, both sides),
and Pishu (BL20, both sides). Each patching time lasted
1–3 h, depending on the patient’s tolerance. When drug
cakes were removed, patients typically exhibited local skin
redness and experienced slight burning sensations. Subse-
quent water exposure, including bathing, was avoided for
1–2 h following treatment to prevent skin aggravation.
Patient drug tolerance varies, and adhering the cake for too
long occasionally led to blisters. Blisters resulting from this
treatment were coated with povidone iodine syrup and
were protected with sterile gauze bandages.
Outcome evaluation
Clinical symptoms were indexed as follows: (1) assess
symptoms before the first acupoint herbal plaster
application, (2) determine rhinoconjunctivitis and rhin-
itis symptoms at the third and fourth acupoint herbal
plaster applications. Clinical outcomes were evaluated
using the RQLQ, which has been proven to be effective
[14, 31] and includes 28 questions in 7 categories. The
RQLQ was designed to measure the impact of rhinitis
on quality of life. It considers that allergic rhinitis
patients often are troubled by nasal symptoms, eye
symptoms, sleep problems, emotional problems, social
issues, and other symptoms [14, 29].
ImmunoCAP Phadiatop blood test
Prior to treatment at Chang Gung Memorial Hospital,
all 23 allergic rhinitis patients were assessed by clinical
pathologists using the ImmunoCAP Phadiatop blood
test. Patients were evaluated for the presence of IgE anti-
bodies against the following allergens: Dermatophagoides
pteronyssinus, cat dander, dog dander, the German cock-
roach, and Moulds. Detection of IgE antibodies exceed-
ing 0.35 kUA/L indicated a positive result.
RNA extraction and microarray
Patient peripheral blood samples were obtained in 5-ml
volumes at the following 6 times (T0–T5) during the
study: (1) before (T0) and 24 h after the first (T1) acu-
point herbal plaster application; (2) before (T2) and 24 h
after the third (T3) acupoint herbal plaster application;
and (3) before the fourth (T4) and 24 h after the fourth
(T5) acupoint herbal plaster application.
From each 5-ml blood sample, 2.5-ml aliquots were ana-
lyzed by the Clinical Pathology Department of Chang Gung
Memorial Hospital for the following: complete blood count/
differential count (CBC/DC):total white blood count;
differential counts for neutrophils, lymphocytes, monocytes,
eosinophils, and basophils; red blood cell count; platelet
count; hemoglobin, hematocrit, and erythrocyte indices
(mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration, and red cell
distribution width [RDW]). Total serum IgE levels were
tracked before the first acupoint herbal plaster application
and 24 h after the fourth acupoint herbal plaster application.
The remaining 2.5-ml blood samples were stored at
room temperature in PAXgene Blood RNA collection
tubes (Qiagen, Valencia, CA, USA), containing an RNA
stabilizer. RNA was extracted from blood samples using
the PAXgene Blood RNA System (Qiagen), according to
the manufacturer’s recommendations, and samples were
stored at −80 °C. RNA samples then were isolated using
an RNeasy MinElute kit (Qiagen), and RNA quality and
quantity were analyzed using a Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA).
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Owing to the IRB’s limitation that no more than 5-ml
peripheral blood could be collected from each study
volunteer, we were unable to obtain sufficient RNA
quantities to analyze individual participants. Therefore,
we applied pre-amplification pooled mRNA samples to a
single microarray chip, a method that has been used
frequently in microarray analysis [23]. Although pooling
could potentially confound signals by mixing cell popu-
lations and individuals, it avoids variation within individ-
uals [32]. Because a microarray using pooled RNA only
identifies genes that change dramatically, this approach
highlights the most differentially expressed signaling
pathways between diseased and control individuals [25].
In our study, equal quantities of mRNA were pooled
from individuals with similar clinical diagnosis and IgE
levels, thereby increasing RNA homogeneity. Each
pooled sample corresponded to the blood RNA from 2
to 3 patients. Samples were analyzed using a GeneChip
Human Genome U133 Plus2 array (Affymetrix, Santa
Clara, CA, USA) containing approximately 54,675
probes. Samples from the 23 patients were divided into
7 pooled groups for each of the 6 blood collection time
points and were applied to 42 chips.
Statistical analysis
Changes in RQLQ and IgE were compared to the first
time point (T0; before first herbal plaster) via a paired
Student’s t-test and a Mann Whitney U-test, respectively.
Microarray data analysis
Unsupervised (hierarchical clustering and principal
component analysis) and supervised (Student’s t-test)
methods have traditionally been used to analyze gene-
expression data [33]. In this study, data were analyzed by
hierarchical clustering using Cluster and TreeView soft-
ware [34] with the following parameters: (1) standard
deviation > 0.4 as the filtering cutoff point (1852 genes
with marked changes selected among 35 arrays); (2)
mean-centered genes and normalized genes; and (3)
cluster analysis conducted using uncentered correlation
of arrays. Cluster and TreeView programs were down-
loaded from http://bonsai.hgc.jp/~mdehoon/software/
cluster. The Student’s t-test, Mann–Whitney U-test
and PCA were performed using MATLAB version 7.4
and Statistics Toolbox version 3.1 (The MathWorks,
Boston, MA, USA). A volcano plot was constructed
using MATLAB to identify changes in replicate
microarray data [35]. Specifically, the negative log of
the p value (−log10[p value]) was plotted on the y-
axis, and the log2 ratio of the fold change was plotted
on the x-axis.
We evaluated genes that were differentially expressed
following acupoint herbal plaster applications (T1, T2,
T3, T4, T5, are compared with T0). Changes in specific
gene expression before and after treatment could suggest
potential immune mechanisms associated with acupoint
herbal plaster application. RQLQ results were compared
with gene expression differences in the final analysis.
Network visualization and analysis
The MetaCore analytical suite (GeneGo, St. Joseph, MI,
USA) was used to compare differences in gene expres-
sion networks [36–39]. MetaCore evaluates systems biol-
ogy and drug development at the computational level,
enabling analyses of human protein–protein interactions
and mechanisms using the database. This suite contrib-
utes to analyses of regulatory networks and signaling
pathway gene groups. To perform a network analysis of
gene groups, MetaCore can work from an input list of
genes and can randomly assign genes to different nodes
to assess the probability of an interacting network [37].
In this study, the list of genes represented on the
Affymetrix Human U133 Plus2 array was used as a base
gene list to calculate p values using MetaCore
procedures. MetaCore uses a hypergeometric model to
determine significance [38, 39].
Results
Clinical outcomes of acupoint herbal plaster treatment
An otolaryngologist screened 23 study participants with
allergic rhinitis, and the GMRCL conducted oligonucleo-
tide chip experiments. Each participant’s diagnosis of per-
ennial allergic rhinitis also was confirmed using anterior
nasal endoscopy. Based on the results of an ImmunoCAP
Phadiatop blood test of allergen-specific IgE, the 23 volun-
teers were classified as either Ph-positive (19 participants)
or Ph-negative (4 participants) (Table 1). Assessments of
clinical symptoms and IgE indices were performed before
the first, third, and after the fourth acupoint herbal plaster
application. The RQLQ was used to survey the patients,
and the results were statistically analyzed for clinical
symptoms [14] (Tables 2 and 3).
In the Ph-positive group, the RQLQ results were
compared before the first and after the fourth acupoint
herbal plaster treatment. We identified significant
improvements in six of the seven domains (activity, non-
hay fever symptoms, eye symptoms, practical problems,
nasal symptoms, and emotional symptoms) examined by
the RQLQ (Tables 2 and 3). In the Ph-negative group,
only two categories (nasal symptoms, emotional
symptoms) appeared to improve following acupoint
treatment. These results suggest that acupoint herbal
plaster applications evoke distinct physiological re-
sponses in these two patient groups. These findings are
consistent with our previous studies regarding
acupuncture treatment for allergic rhinitis [16, 17].
Total serum IgE values were compared before the first
and after the fourth acupoint herbal plaster application
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(Tables 4 and 5). Following the course of herbal plaster
treatments, total IgE levels were unchanged in both the
Ph-positive and -negative groups (Tables 4 and 5). This
is consistent with previous short-term studies by our la-
boratory [16, 17] and others [40], which found that total
serum IgE levels in allergic rhinitis patients treated with
TCM did not change.
Ph-positive and Ph-negative allergic rhinitis patients ex-
hibit distinct gene expression profiles following acupoint
herbal plaster treatment
Since Ph-positive and Ph-negative groups exhibited differ-
ent clinical outcomes, we explored the gene expression
profiles of these two patient groups following acupoint
herbal plaster treatment. Total RNA was extracted from
peripheral blood samples at each of the 6 time points
analyzed (23 patients, 138 RNA samples total). Because of
insufficient blood RNA quantities (1–2 μg/subject), we
pooled sets of 2–3 RNA samples from subjects with simi-
lar clinical indices, resulting in seven pooled RNA samples
for each of the six time points. The 42 pooled RNA
samples were applied to GeneChip Human Genome U133
Plus 2.0 arrays. Patient and sample information are
detailed in Table 6.
To estimate the effects of acupoint herbal plaster
treatment, the gene expression level at each treatment
point was subtracted from the first time point (T0;
before herbal plaster treatment). After filtering the low-
intensity non-significant genes (standard deviation < 0.4),
1852 genes remained for analysis with non-supervised hier-
archical clustering methods. We identified distinct gene
expression profiles in Ph-positive and -negative patients
using a hierarchical approach (Fig. 1a). We further analyzed
the correlation matrix for all 35 samples using a PCA [41].
The three-dimensional plot of the first three principal com-
ponents by the matrix containing 80 % of the information
Table 1 Comparison of baseline characteristics between Ph-positive









Female 9 1 0.60^
Age 32.11 5.37 35 3.37 0.22
Duration of allergic rhinitis
≥ 10 years 14 3
< 10 years 5 1 0.96^
Activity 3.12 1.39 3.08 1.32 0.66
Sleep 1.65 1.09 1.58 0,92 0.64
Non-hay fever
symptoms
2.39 1.14 2.25 1.08 0.58
Practical problems 2.84 1.42 2.33 1.61 0.38
Nasal symptoms 2.78 1.17 2.94 1.43 0.98
Eye symptoms 2.37 1.41 1.75 1.14 0.24
Emotional
symptoms
2.08 1.15 1.38 0.92 0.15
Overall score 2.46 1.02 2.19 0.96 0.40
IgE (Baseline) 302.12 78.75 21.25 7.70 0.002**
IgE (Follow-up) 333.61 86.01 25.10* 10.44 0.005**
SD Standard Deviation
Note: *p < 0:05, **p < 0:01 (Mann–Whitney U test)
^Fisher’s exact test
Table 2 Changes in RQLQ results following the third and fourth
herbal plaster (hp) treatments in Ph-positive patients














Activity 3.12 2.56 0.1322 2.09 0.0002**
Sleep 1.65 1.58 0.8488 1.35 0.0804
Non-hay fever
symptoms
2.39 2.02 0.1465 1.64 0.0012**
Practical problems 2.84 2.39 0.1549 2.05 0.0018**
Nasal symptoms 2.78 2.30 0.1006 1.92 0.0000**
Eye symptoms 2.37 1.57 0.0330* 1.29 0.0066**
Emotional
symptoms
2.08 1.62 0.0634 1.33 0.0010**
Overall score 2.46 2.00 0.0635 1.67 0.0000**
Paired Student’s t-test; n = 19, *p < 0.05 **p < 0.01
Table 3 Changes in RQLQ results following the third and fourth
herbal plaster (hp) treatments in Ph-negative patients












Activity 3.08 1.58 0.0577 1.33 0.0800
Sleep 1.58 1.58 1.0000 1.17 0.3677
Non-hay fever
symptoms
2.25 1.79 0.3477 1.21 0.0564
Practical
problems
2.33 1.67 0.3994 1.33 0.1135
Nasal symptoms 2.94 2.06 0.1881 1.31 0.0065**
Eye symptoms 1.75 1.19 0.4338 1.19 0.4594
Emotional
symptoms
1.38 1.06 0.5551 0.69 0.0486*
Overall score 2.19 1.56 0.1940 1.18 0.0371*
Paired Student’s t-test; n = 4, *p < 0.05 **p < 0.01
Table 4 Changes in total IgE levels following the fourth herbal
plaster (hp) treatment in Ph-positive patients
No. Baseline Follow-up P value^
Mean ± SD Mean ± SD
IgE 19 302.12 ± 78.75 333.61 ± 86.01 0.085
SD Standard Deviation
^Mann–Whitney U-test
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is shown in Fig. 1b. This analysis indicated that the Ph-
positive and -negative groups were distinct in their re-
sponses to acupoint herbal plaster treatment. Because the
hierarchical clustering and PCA suggested that the M4-2
and M4-4 samples were outliers in the Ph-positive group,
these samples were excluded from further analysis.
Since, the clinical outcomes (RQLQ) after treatment in
the Ph-positive and -negative groups differed, we explored
the gene expression profiles for these two groups in
response to acupoint herbal plaster application. We used a
volcano plot to obtain an overview of the 1852 filtered
genes (Fig. 2a), and we selected 89 genes that exhibited
fold-changes exceeding 20.75 = 1.682 (p < 0.01, Student’s
t-test) between Ph-positive and -negative participants
(Fig. 2b and Table 7). These genes were examined using
MetaCore software (http://lsresearch.thomsonreuters.com/
pages/solutions/1/metacore) for reaction pathway ana-
lysis, and the pathways “Immune response_IL-13 signaling
via JAK-STAT (Janus kinase and signal transducers and ac-
tivators of transcription)” and “Inflammation_Interferon
signaling” were identified to correspond to the down- and
up-regulated genes, respectively, in the Ph-positive group
(Fig. 2b and Table 8).
Differentially expressed genes after acupoint herbal
plaster treatment in Ph-positive patients
The RQLQ indicated that the clinical efficacy of herbal
plaster treatment was different between Ph-positive patients
and Ph-negative patients. Then we evaluated genes that
were differentially expressed following acupoint herbal plas-
ter applications (T1, T2, T3, T4, T5, are compared with T0)
in Ph-positive patients. Since the differentially expresse in
Ph-positive group is less than Ph-positive group compared
with Ph-negative group. We selected 47 genes that exhib-
ited p < 0.01 (via Student’s t-test) and fold changes (vs. T0)
of 20.4 = 1.320 (Fig. 3 and Table 9). Globally, most genes
were down-regulated (45/47) after herbal plaster treatment.
This result was consistent with our previous report that
most genes were down-regulated after acupuncture treat-
ment in Ph-positive allergic rhinitis patients [17].
These 45 genes then were input to the MetaCore
reaction pathways analysis. The data indicated that
Ph-positive allergic rhinitis patients who received acu-
point herbal plaster applications significantly induced
several pathways (p < 0.01; Table 10). Among the 45 down-
regulated genes, pathway analysis identified significant
involvement of the “Oxidative phosphorylation pathway”
(p < 0.0001). Network analysis also identified “Protein
folding_Response to unfolded proteins,” “Immune response
Antigen presentation,” and “Immune response Phagosome
in antigen presentation” as significant (p < 0.001) relative to
the 45 down-regulated genes.
Discussion
Allergic rhinitis likely results from an imbalance in the Th1
and Th2 cell-mediated inflammatory responses [20, 21]. In
addition to the hygiene hypothesis causing deviation of the
Th1 and Th2 balance and reduced immune suppression,
investigators have implicated decreases in T-regulatory
(Treg) activity in allergy diseases [42, 43]. People suffering
from allergies, usually have a reduced Th1 reaction and a
predominant Th2 response. Th1 cells tended to decrease in
patients with allergic rhinitis, whereas Th2 cells were sig-
nificantly increased. Significant deviations from the normal
Th1/Th2 ratio may be associated with the incidence of
allergic diseases [18, 20, 44]. A study examining allergic in-
flammation that focused on Th2 cytokines (IL-4, IL-5, IL-9,
and IL-13) reported that these cytokines recruited cells that
induced allergic inflammation via chemokine secretion
[44]. Few reports have described human allergic inflamma-
tion with respect to cytokine antagonists [19, 21, 45].
Table 5 Changes in patient total IgE levels following the fourth
herbal plaster (hp) treatment in Ph-negative patients
No. Baseline Follow-up P value^
Mean ± SD Mean ± SD
IgE 4 21.25 ± 7.70 25.10 ± 10.44 0.63
SD Standard Deviation
^Mann–Whitney U-test
Table 6 Pooling strategy for RNA samples. The first number in each cell indicates the group type, and the second indicates the













Ph(+) M1-1 M1-2 M1-3 M1-4 M1-5 M1-6
Ph(+) M2-1 M2-2 M2-3 M2-4 M2-5 M2-6
Ph(+) M3-1 M3-2 M3-3 M3-4 M3-5 M3-6
Ph(+) M4-1 M4-2 M4-3 M4-4 M4-5 M4-6
Ph(+) M5-1 M5-2 M5-3 M5-4 M5-5 M5-6
Ph(+) M6-1 M6-2 M6-3 M6-4 M6-5 M6-6
Ph(−) M7-1 M7-2 M7-3 M7-4 M7-5 M7-6
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Although strengthening the Th1 response is regarded as a
novel therapeutic approach for allergic rhinitis, this method
has not been applied clinically [19, 21]. A restructuring of
the Th1 and Th2 responses in patients with allergic rhinitis
may be accomplished with acupuncture [16, 17]. Studies
have shown that acupuncture treatment of allergic inflam-
mation can maintain the equilibrium between Th1 and
Th2 cells and between Tregs and Th2 cells [16, 17].
Many patients choose acupoint herbal plaster treat-
ments for allergic rhinitis in Taiwan [3–5] and mainland
China [6, 7]. We previously examined the efficacy of
acupoint herbal plaster treatment for allergic rhinitis
[13]. The present study is the first to apply the RQLQ to
comprehensively assess the effects of acupoint herbal
plaster on allergic rhinitis symptoms. Our results suggest
that acupoint herbal plaster is a safe, effective, and
convenient treatment for allergic rhinitis. A comparison
of baseline characteristics before treatment between
Ph-positive and Ph-negative patients showed no differ-
ences, with the exception of total IgE levels (Table 1).
The RQLQ results after the fourth treatment of 19
Ph-positive patients indicated symptom improvements
in six of seven categories (activity, non-hay fever symp-
toms, practical problems, nasal symptoms, eye symp-
toms, emotional symptoms; Tables 2 and 3). In contrast,
the four Ph-negative volunteers (−) reported symptom
improvements in only two categories (nasal symptoms,
emotional symptoms; Tables 2 and 3). These results are
similar to those found in our previous report on acu-
































Fold Change (log2 Ratio)
a
b
Fig. 2 a Volcano plot of the 1852 filtered genes and b functional and
clustering analyses of the differentially expressed genes between
Ph-positive and -negative groups. a In the volcano plot, the -log10(P
value) is plotted on the y-axis, and the log2 ratio of the fold change is
plotted on the x-axis. In total, 89 genes (red points) that exhibited
fold-changes exceeding 20.75 = 1.682 between Ph-positive and -negative
groups were selected from the 1852 filtered genes (p< 0.01, Student’s
t-test). b The 89 differentially expressed genes were analyzed with
MetaCore software, and “Immune response_IL-13 signaling via JAK-STAT”
and “Inflammation_Interferon signaling” pathways were found to
correspond to up- and down-regulated genes, respectively, in
Ph-positive patients. The genes involved in pathway are indicated
with arrows
Fig. 1 Distinct gene expression profiles in Ph-positive and -negative
patient groups as determined by a hierarchical clustering and b principle
component analysis. a Each column represents a chip, and each row
represents a specific gene. The gene expression level at each treatment
point was subtracted from the first time point (T0). The color map uses
red and green for high and low expression values, respectively. Black
corresponds to genes exhibiting non-significant variation. b Three-
dimensional plot of the first three principal components by the matrix
containing 80 % of the information. Ph-positive and -negative patients
are indicated as closed squares and open circles, respectively
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Table 7 The 89 genes that were differentially expressed between Ph-positive and Ph-negative patients with allergic rhinitis following
treatment with acupoint herbal paste
ID Gene Symbol Gene Title Fold changea P value
1552288_at CILP2 cartilage intermediate layer protein 2 1.45 3.4E-05
1556590_s_at NA NA 1.32 1.4E-04
1557195_at NA NA 1.31 8.8E-04
1557761_s_at LOC400794 hypothetical LOC400794 1.31 3.9E-06
1562216_at NA NA 1.30 1.7E-04
1565913_at NA NA 1.21 4.2E-10
1566134_at CARHSP1 Calcium regulated heat stable protein
1, 24 kDa
1.20 6.5E-04
1566964_at NA NA 1.18 3.4E-04
1567240_x_at OR2L2 olfactory receptor, family 2, subfamily
L, member 2
1.11 7.1E-03
1569482_at NA NA 1.08 8.8E-03
200038_s_at RPL17 ribosomal protein L17 1.08 7.4E-04
200082_s_at RPS7 ribosomal protein S7 1.06 3.7E-03
200705_s_at EEF1B2 eukaryotic translation elongation factor
1 beta 2
1.02 2.6E-03
200986_at SERPING1 serpin peptidase inhibitor, clade G
(C1 inhibitor), member 1
1.02 2.0E-03
201699_at PSMC6 proteasome (prosome, macropain) 26S
subunit, ATPase, 6
1.01 4.0E-03
202086_at MX1 myxovirus (influenza virus) resistance
1, interferon-inducible protein p78 (mous
1.01 7.2E-09
202411_at IFI27 interferon, alpha-inducible protein 27 1.00 7.8E-05
202635_s_at POLR2K polymerase (RNA) II (DNA directed)





204415_at IFI6 interferon, alpha-inducible protein 6 0.97 7.6E-05
204439_at IFI44L interferon-induced protein 44-like 0.96 2.0E-03
204732_s_at TRIM23 tripartite motif-containing 23 0.93 1.7E-03
205849_s_at UQCRB ubiquinol-cytochrome c reductase binding
protein
0.91 7.7E-03
205914_s_at GRIN1 glutamate receptor, ionotropic, N-methyl
D-aspartate 1
0.90 1.5E-03
206584_at LY96 lymphocyte antigen 96 0.90 1.2E-04
207723_s_at KLRC3 killer cell lectin-like receptor subfamily C,
member 3
0.88 3.6E-04
208792_s_at CLU clusterin 0.88 3.5E-03
209160_at AKR1C3 aldo-keto reductase family 1, member C3
(3-alpha hydroxysteroid dehydrogenase, t
0.88 3.9E-06
209651_at TGFB1I1 transforming growth factor beta 1 induced
transcript 1
0.86 1.0E-03
209732_at CLEC2B C-type lectin domain family 2, member B 0.86 3.7E-03
209743_s_at ITCH itchy E3 ubiquitin protein ligase homolog
(mouse)
0.85 2.3E-03
209795_at CD69 CD69 molecule 0.85 3.9E-08
210103_s_at FOXA2 forkhead box A2 0.84 9.9E-04
210432_s_at SCN3A sodium channel, voltage-gated, type III,
alpha subunit
0.83 2.8E-04
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Table 7 The 89 genes that were differentially expressed between Ph-positive and Ph-negative patients with allergic rhinitis following
treatment with acupoint herbal paste (Continued)
210548_at CCL23 chemokine (C-C motif) ligand 23 0.83 8.5E-05
210639_s_at ATG5 ATG5 autophagy related 5 homolog
(S. cerevisiae)
0.82 1.7E-07
210873_x_at APOBEC3A apolipoprotein B mRNA editing
enzyme, catalytic polypeptide-like 3A
0.82 2.7E-04
211968_s_at HSP90AA1 heat shock protein 90 kDa alpha
(cytosolic), class A member 1
0.81 8.0E-05
212270_x_at RPL17 ribosomal protein L17 0.81 2.9E-04
212537_x_at RPL17 ribosomal protein L17 0.78 1.6E-03
213226_at CCNA2 cyclin A2 0.78 4.2E-03
214070_s_at ATP10B ATPase, class V, type 10B 0.78 3.3E-03
215101_s_at CXCL5 chemokine (C-X-C motif) ligand 5 0.78 6.0E-03
215394_at PIK3C3 phosphoinositide-3-kinase, class 3 0.77 6.3E-10
215646_s_at VCAN versican 0.77 4.3E-04
216412_x_at LOC100290557 similar to hCG91935 0.77 1.3E-03
216834_at RGS1 regulator of G-protein signaling 1 0.76 2.3E-03
217915_s_at RSL24D1 ribosomal L24 domain containing 1 0.76 9.8E-04
219519_s_at SIGLEC1 sialic acid binding Ig-like lectin 1,
sialoadhesin
0.76 4.7E-04
219551_at EAF2 ELL associated factor 2 0.76 3.1E-03
220141_at C11orf63 chromosome 11 open reading frame 63 0.75 5.8E-03
220184_at NANOG Nanog homeobox −0.75 3.9E-03
220646_s_at KLRF1 killer cell lectin-like receptor subfamily
F, member 1
−0.75 3.9E-11
220827_at NA NA −0.76 1.6E-03
222229_x_at RPL26 ribosomal protein L26 −0.77 5.9E-05
222465_at RSL24D1 ribosomal L24 domain containing 1 −0.78 1.5E-03
223963_s_at IGF2BP2 insulin-like growth factor 2 mRNA
binding protein 2
−0.79 2.5E-04
224293_at TTTY10 testis-specific transcript, Y-linked 10
(non-protein coding)
−0.79 8.6E-03
225541_at RPL22L1 ribosomal protein L22-like 1 −0.80 4.7E-03
226344_at ZMAT1 zinc finger, matrin type 1 −0.81 1.4E-04
227454_at TAOK1 TAO kinase 1 −0.81 9.4E-04
227766_at LIG4 ligase IV, DNA, ATP-dependent −0.82 9.9E-03
228174_at SCAI suppressor of cancer cell invasion −0.83 8.5E-03
228439_at BATF2 basic leucine zipper transcription
factor, ATF-like 2
−0.83 9.6E-03
228970_at ZBTB8OS zinc finger and BTB domain
containing 8 opposite strand
−0.86 1.1E-07
229431_at RFXAP regulatory factor X-associated protein −0.86 8.8E-03
229437_at MIR155HG MIR155 host gene (non-protein coding) −0.87 4.5E-04
229893_at FRMD3 FERM domain containing 3 −0.89 7.0E-03
229910_at SHE Src homology 2 domain containing E −0.89 2.0E-03
230153_at NEK9 NIMA (never in mitosis gene a)-
related kinase 9
−0.89 6.2E-09
231014_at TRIM50 tripartite motif-containing 50 −0.89 4.8E-03
231038_s_at NA NA −0.92 8.1E-03
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the herbal plaster treatment was noninvasive and easy to
apply. The degree of symptom improvement among Ph-
positive allergic rhinitis patients was different with the
Ph-negative group, indicating that the acupoint herbal
plaster treatment in these patient groups evoked distinct
physiological responses. Due to its preliminary nature,
this study has some limitations including the lack of a
control group or a safety assessment.
In this study, the average total serum IgE levels tended
to increase in Ph-positive and -negative groups following
the fourth herbal plaster treatment, but the changes
were not statistically significant (Table 4 and 5). This
Table 7 The 89 genes that were differentially expressed between Ph-positive and Ph-negative patients with allergic rhinitis following
treatment with acupoint herbal paste (Continued)
231484_at NA NA −0.92 1.5E-04
231688_at MMP8 matrix metallopeptidase 8
(neutrophil collagenase)
−0.93 6.4E-03
231975_s_at MIER3 mesoderm induction early response
1, family member 3
−0.94 1.9E-03
233015_at MBNL1 muscleblind-like (Drosophila) −0.96 3.7E-03
235762_at TAS2R14 taste receptor, type 2, member 14 −0.97 8.7E-05
236495_at NA NA −0.97 8.1E-10
236666_s_at LRRC10B leucine rich repeat containing 10B −0.98 1.1E-05
237689_at SARS Seryl-tRNA synthetase −1.00 1.8E-03
238174_at NA NA −1.01 6.3E-03
238918_at NA NA −1.06 1.7E-03
239655_at NA NA −1.07 4.2E-03
239819_at NA NA −1.08 1.4E-04
240145_at NA NA −1.10 5.3E-03
240262_at NA NA −1.11 4.2E-05
240652_at NA NA −1.20 8.0E-10
240866_at NA NA −1.26 3.8E-03




afold change (Log2 ratio)
Table 8 Metacore process map for the 89 genes that were differentially expressed between Ph-positive and Ph-negative patients
with allergic rhinitis following acupoint herbal paste treatment
Process map of down-regulated genes in Ph(+)
Maps P value Filter Genesa Map genesb
DNA damage_NHEJ mechanisms of DSBs repair 1.4E-02 1 (LIG4) 19
Neurophysiological process_Bitter taste signaling 2.0E-02 1 (TAS2R14) 28
Apoptosis and survival_Granzyme A signaling 2.1E-02 1 (LIG4) 30
Cell cycle_Role of Nek in cell cycle regulation 2.3E-02 1 (NEK9) 32
Development_Role of Activin A in cell
differentiation and proliferation
2.9E-02 1 (NANOG) 40
Immune response_IL-13 signaling via JAK-STAT 3.1E-02 1 (MMP8) 44
Process map of up-regulated genes in Ph(+)
Maps P value Filter Genesa Map genesb
Inflammation_Interferon signaling 1.1E-02 3 (IFI6,IFI27, MX1) 110
Autophagy_Autophagy 2.3E-02 2 (PIK3C3,ATG5) 55
Cell cycle_S phase 2.6E-02 2 (HSP90AA1, CCNA2) 149
aNumber of filter genes in the map
bNumber of genes in the map
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result is similar to that of our previous acupuncture
study [16, 17] and may indicate that reducing total IgE
synthesis is not the primary mechanism of acupoint
herbal plaster treatment of allergic rhinitis.
The Ph-positive and -negative groups exhibited differ-
ent gene expression trends after acupoint herbal plaster
treatment (Fig. 2 and Table 7). This supports the results
of the RQLQ, and indicates that the patient groups re-
spond differently to acupoint herbal plaster.
Pathway analysis of the differentially expressed genes
indicated that “Immune response_IL-13 signaling via
JAK-STAT” and “Inflammation_Interferon signaling”
pathways corresponded to down- and up-regulated
genes, respectively, between Ph-positive and Ph-negative
patients (Fig. 2b and Table 8). Since a Th1/Th2 cytokine
imbalance contributes to the etiology and pathogenesis
of allergic rhinitis, understanding the mechanisms of this
disease will help to find novel targets for therapy. Th1
cells secrete primarily IL-2, IFNγ, IL-3, and GM-CSF,
whereas Th2 cells secrete IL-3, IL-4, IL-5, IL-10, IL-13,
and GM-CSF [22]. Cytokines released after activation of
T-cell receptors interact with cytokine receptors on
mononuclear cells and activate these cells via the JAK-
STAT (Janus kinase and signal transducers and activa-
tors of transcription) pathway. The JAK-STAT pathway
is involved in histamine-mediated regulation of the Th2
cytokines IL-5, IL-10, and IL-13, and of the Th1 cytokine
IFNγ [22]. IL-13 plays a central role in the promotion of
an allergic inflammatory eosinophilic reaction in allergic
diseases via IgE isotype switching. IFNγ down-regulates
the secretion of certain Th2 cytokines [22]. Local admin-
istration of IFNγ in mice prevented antigen-induced eo-
sinophil infiltration into the trachea and normalized
airway function. However, recombinant subcutaneous
administration of IFNγ had no benefit in the treatment
of steroid-dependent asthma [22]. Pathways that down-
regulated IL-13 signaling via JAK-STAT and upregulated
Interferon signaling pathways were differentially
expressed between Ph-positive and Ph-negative patients
with allergic rhinitis after acupoint herbal paste treat-
ment; however, further studies are necessary to confirm
these results.
Several pathways were significantly induced in Ph-
positive allergic rhinitis patients who received
acupoint herbal plaster applications. Phagosomal
immune response in antigen presentation was noted due
to an immune response to the herbal plater treatment
(Table 10). Macrophages function to clear infectious
particles, and this process involves engulfing microbes
into phagosomes where they are lysed and degraded.
Phagosomes are pivotal in linking both the innate and
adaptive immune responses [46]. Phagosomal proteins
regulated by IFNγ include proteins expected to alter
phagosome maturation, enhance microbe degradation,
trigger the macrophage immune response, and promote
antigen loading on major histocompatibility complex
(MHC) class I molecules [46]. IFNγ delays phagosomal
acquisition of lysosomal hydrolases and peptidases to aid
in antigen presentation, which is dependent on
phagosomal networks of the actin cytoskeleton and
vesicle-trafficking proteins, as well as Src kinases and
calpain proteases [47].
In this preliminary study, Ph-positive patients with al-
lergic rhinitis who received acupoint herbal plaster treat-
ments manifested gene expression changes involved in
the “Immune response_IL-13 signaling via JAK-STAT”
pathway. These patients reported improved clinical































Fig. 3 a Volcano plot of the gene expression profiles in the Ph-positive
group and b differentially expressed genes (compared with T0) subjected
to hierarchical clustering analysis. a In the volcano plot, the -log10(P value)
is plotted on the y-axis, and the log2 ratio of the fold change is plotted
on the x-axis. Forty-seven genes (red points) that exhibited fold-changes
of 20.4 = 1.320 (p< 0.01) were selected from the 1852 filtered genes. b In
the cluster plot, each column represents a chip, and each row represents
a specific gene. Most genes were down-regulated (45/47 genes) among
the differentially expressed genes after herbal plaster treatment. The
genes involved in pathway are indicated with arrows
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Table 9 The 47 genes that were differentially expressed as compared to the first time point (T0; before herbal plaster treatment in
the Ph-positive group)
ID Gene Symbol Gene Title Fold changea P value
211969_at HSP90AA1 heat shock protein 90 kDa alpha (cytosolic),
class A member 1
−0.62 5.4E-10
224567_x_at MALAT1 Metastasis associated lung adenocarcinoma
transcript 1 (non-protein coding)
−0.62 3.3E-06
226675_s_at MALAT1 Metastasis associated lung adenocarcinoma
transcript 1 (non-protein coding)
−0.58 1.0E-04
216563_at ANKRD12 Ankyrin repeat domain 12 −0.58 2.8E-04
222465_at RSL24D1 ribosomal L24 domain containing 1 −0.58 1.6E-06
204732_s_at TRIM23 tripartite motif-containing 23 −0.56 2.8E-07
201304_at NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5, 13 kDa
−0.52 6.9E-07
203491_s_at CEP57 centrosomal protein 57 kDa −0.52 3.5E-06
235643_at SAMD9L sterile alpha motif domain containing 9-like −0.52 1.7E-04
209662_at CETN3 centrin, EF-hand protein, 3 (CDC31
homolog, yeast)
−0.51 2.3E-04
212417_at SCAMP1 secretory carrier membrane protein 1 −0.50 4.5E-04
217915_s_at RSL24D1 ribosomal L24 domain containing 1 −0.49 2.6E-06
200598_s_at HSP90B1 heat shock protein 90 kDa beta (Grp94),
member 1
−0.49 3.6E-07
242429_at ZNF567 zinc finger protein 567 −0.49 1.8E-05
232958_at NA NA −0.48 5.6E-05
222326_at NA NA −0.48 2.0E-05
200026_at RPL34 ribosomal protein L34 −0.47 3.1E-03
221765_at UGCG UDP-glucose ceramide glucosyltransferase −0.47 3.1E-04
212794_s_at KIAA1033 KIAA1033 −0.46 1.0E-06
200099_s_at RPS3A ribosomal protein S3A −0.46 2.2E-04
203153_at IFIT1 interferon-induced protein with
tetratricopeptide repeats 1
−0.46 2.9E-04
211968_s_at HSP90AA1 heat shock protein 90 kDa alpha (cytosolic),
class A member 1
−0.45 5.6E-06
226800_at EFCAB7 EF-hand calcium binding domain 7 −0.45 9.2E-09
225312_at COMMD6 COMM domain containing 6 −0.44 6.1E-03
201699_at PSMC6 proteasome (prosome, macropain) 26S
subunit, ATPase, 6
−0.44 4.4E-07
222848_at CENPK centromere protein K −0.44 2.4E-05
212587_s_at PTPRC protein tyrosine phosphatase, receptor
type, C
−0.43 1.7E-04
219239_s_at ZNF654 zinc finger protein 654 −0.43 3.0E-07
205849_s_at UQCRB ubiquinol-cytochrome c reductase
binding protein
−0.43 2.7E-03
214453_s_at IFI44 interferon-induced protein 44 −0.43 6.8E-05
227152_at C12orf35 chromosome 12 open reading frame 35 −0.43 7.2E-05
200061_s_at RPS24 ribosomal protein S24 −0.42 5.8E-03
205809_s_at WASL Wiskott-Aldrich syndrome-like −0.42 4.0E-05
222616_s_at USP16 ubiquitin specific peptidase 16 −0.42 6.0E-07
219356_s_at CHMP5 chromatin modifying protein 5 −0.42 2.4E-05
244042_x_at NA NA −0.41 4.0E-05
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symptoms of allergic rhinitis according to the RQLQ
scale. Pathway analysis suggested that allergic rhinitis
patients treated with acupoint herbal plaster improved
their balance of Th1-derived pro-inflammatory cytokines
versus Th2-derived anti-inflammatory cytokines. Our
results indicate that acupoint herbal plaster application
diminished allergic inflammation by maintaining an
appropriate equilibrium between Th1 and Th2 cells.
Conclusions
RQLQ and gene expression profiles indicated that
patients with Ph-positive and -negative allergic rhinitis
exhibit distinct physiological responses after receiving
acupoint herbal plaster treatments. Gene expression
levels were compared before and after acupoint herbal
plaster application and in Ph-positive versus Ph-negative
participants. In this preliminary study, we find that the
IL-13 immune response via JAK-STAT signaling and
interferon inflammation signaling were down- and
upregulated, respectively, in the Ph-positive group.
Further studies are required to verify these pathways in
Ph-positive patients, and to determine the mechanism of
such pathway dysregulation.
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Table 9 The 47 genes that were differentially expressed as compared to the first time point (T0; before herbal plaster treatment in
the Ph-positive group) (Continued)
205871_at PLGLA plasminogen-like A −0.41 1.4E-06
235653_s_at THAP6 THAP domain containing 6 −0.41 1.7E-06
219387_at CCDC88A coiled-coil domain containing 88A −0.41 6.8E-05
202110_at COX7B cytochrome c oxidase subunit VIIb −0.41 4.0E-03
209795_at CD69 CD69 molecule −0.41 4.5E-05
224786_at SCOC short coiled-coil protein −0.40 2.4E-03
221728_x_at XIST X (inactive)-specific transcript
(non-protein coding)
−0.40 3.2E-05
214218_s_at XIST X (inactive)-specific transcript
(non-protein coding)
−0.40 3.9E-04
212391_x_at RPS3A ribosomal protein S3A −0.40 3.6E-04
202411_at IFI27 interferon, alpha-inducible protein 27 0.41 6.5E-03
228582_x_at MALAT1 Metastasis associated lung adenocarcinoma
transcript 1 (non-protein coding)
0.49 5.8E-03
NA Not Available
afold change (Log2 ratio)
Table 10 Metacore process map for the 45 genes that were
down-regulated in Ph-positive patients with allergic rhinitis
following acupoint herbal paste treatment
Process map of down-regulated genes in Ph(+)



















aNumber of filter genes in the map
bNumber of genes in the map
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